Home / Anti-infectives / Daclatasvir
ATC J05AP07 · Antivirals for treatment of HCV infections
Daclatasvir shortage
As of 2 Nov 2026, Daclatasvir has a reported shortage in 1 of the 15 countries we track (Canada), covering 2 products from 1 company.
Countries1/15
Products2packs or presentations
Companies11 listed
Short since–
Earliest returnnot givencompany estimate
Main reasonNot stated
United StatesNo reported shortageCanada2 products shortGermanyNo reported shortageFranceNo reported shortageItalyNo reported shortageSpainNo reported shortageIrelandNo reported shortageAustriaNo reported shortageBelgiumNo reported shortageSwitzerlandNo reported shortageCzechiaNo reported shortageNorwayNo reported shortageSwedenNo reported shortageJapanNo reported shortageAustraliaNo reported shortage
Which companies are short
products short, all countriesListed: Bristol Myers Squibb BMY · NYSE
Compared with similar medicines
ATC group J05AP · Antivirals for treatment of HCV infectionsAffected products
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| CA | DAKLINZA (1 Bottle X 28) discontinuation | BRISTOL-MYERS SQUIBB CANADA | not given | not given | Not stated |
| CA | DAKLINZA (1 Bottle X 28) discontinuation | BRISTOL-MYERS SQUIBB CANADA | not given | not given | Not stated |
"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.